| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5894d694d4a784d601f503d79e518f2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate |
2014-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9ccc15803e6b7bef0a47351dd6d19a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b54852a7fb9262defd052d1dde46ded
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67d001b26a8170eff79e941388247c20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e941fa9dda3ef63a0692800278e98f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b79cefadf4db089150aa7b403c22e0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66c3f7da5e366f04fa822105a01a64cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea8d6c0c1b103ca0498169ec27927131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50d952eb1d5ac9ab233cecdf3865d67f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f2c347945357d0a2af6c47b6283742f |
| publicationDate |
2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2799439-T3 |
| titleOfInvention |
Compositions for the treatment of rheumatoid arthritis and methods of using them |
| abstract |
An anti-IL6R antibody comprising the heavy chain variable region of SEQ ID NO: 2 and the light chain variable region of SEQ ID NO: 3 for use in combination with methotrexate to inhibit the progression of structural damage in a subject suffering from rheumatoid arthritis, wherein an effective amount of the antibody and an effective amount of methotrexate are administered to the subject, and wherein the antibody is administered subcutaneously to the subject between 150 and 200 mg every two weeks. |
| priorityDate |
2013-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |